Regeneron Pharmaceuticals (REGN) Current Assets (2009 - 2026)
Regeneron Pharmaceuticals (REGN) posted quarterly Current Assets of $18.4 billion for Q2 2026, up 9.41% year-over-year from $16.9 billion in Q2 2025, and up 1.3% quarter-over-quarter from $18.2 billion in Q1 2026.
Regeneron Pharmaceuticals (REGN) Current Assets (2009 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' Current Assets history runs 18 years deep, the most recent figure standing at $18.4 billion for Q2 2026.
- In Q2 2026, Current Assets rose 9.41% year-over-year to $18.4 billion; the TTM figure through Jun 2026 stood at $18.4 billion (up 9.41% YoY), while the FY2025 annual figure was $18.0 billion, down 3.42% from the prior year.
- Current Assets for Q2 2026 stood at $18.4 billion, up from $18.2 billion in the prior quarter.
- The five-year high for Current Assets was $19.5 billion in Q4 2023, with the low at $14.3 billion in Q1 2022.
- The 5-year median for Current Assets is $18.0 billion (2025), against an average of $17.6 billion.
- The sharpest annual moves came in 2022 and 2025: Current Assets jumped 42.28% in 2022, then retreated 11.65% in 2025.
- Regeneron Pharmaceuticals' Current Assets stood at $15.9 billion in 2022, then rose by 22.63% to $19.5 billion in 2023, then decreased by 4.2% to $18.7 billion in 2024, then dropped by 3.42% to $18.0 billion in 2025, then increased by 2.35% to $18.4 billion in 2026.
- Business Quant data shows REGN's Current Assets at $18.4 billion in Q2 2026, $18.2 billion in Q1 2026, and $18.0 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 4.74 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18.45 Bn |
| Mar 31, 2026 | 18.21 Bn |
| Dec 31, 2025 | 18.02 Bn |
| Sep 30, 2025 | 17.98 Bn |
| Jun 30, 2025 | 16.86 Bn |
| Mar 31, 2025 | 17.57 Bn |
| Dec 31, 2024 | 18.66 Bn |
| Sep 30, 2024 | 19.33 Bn |
| Jun 30, 2024 | 19.08 Bn |
| Mar 31, 2024 | 18.87 Bn |
| Dec 31, 2023 | 19.48 Bn |
| Sep 30, 2023 | 18.63 Bn |
| Jun 30, 2023 | 16.92 Bn |
| Mar 31, 2023 | 16.91 Bn |
| Dec 31, 2022 | 15.88 Bn |
| Sep 30, 2022 | 15.43 Bn |
| Jun 30, 2022 | 15.53 Bn |
| Mar 31, 2022 | 14.31 Bn |
| Dec 31, 2021 | 14.01 Bn |
| Sep 30, 2021 | 13.78 Bn |